- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAWS
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announces that it has successfully raised EUR 32.3 million in gross proceeds through a significantly oversubscribed private placement to institutional investors via an accelerated book building. Medigene issued 2,230,000 new shares from authorized capital, representing approximately 10% of the currently outstanding shares. Shares were allocated to institutional investors at a price of EUR 14.50 per share which represents a 2.3% discount to the last closing price. This financing will increase the total number of registered shares to 24,544,595.
Concomittantly, QVT Financial LP, USA, a major shareholder of Medigene, has agreed to sell 1,105,490 existing shares of Medigene in a secondary offering to institutional investors at the same price of EUR 14.50 per share as part of a general restructuring across all QVT funds. These shares were fully placed. After the completion of this transaction QVT, will hold over 4% of Medigene's total outstanding share capital (previously 9.5%), thus remaining a major shareholder of Medigene. Keith Manchester, Managing Director and Head of Life Sciences for QVT Financial, remains a member of Medigene's Supervisory Board.
The issuance of new shares was resolved by the Executive Management Board and the Supervisory Board of Medigene by today's resolutions.
Contact Medigene AG
Julia Hofmann, Head of Investor Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Lochhamer Straße 11
|Contact Person:||Julia Hofmann, Head of Public and Investor Relations|
|Phone:||+49 89 200033-3301|
|Stock Exchange(s):||Regulated Market in Frankfurt, Free Market in Berlin, Free Market in Dusseldorf, Free Market in Hamburg, Free Market in Hannover, Free Market in Munich, Free Market in Stuttgart, Open Market in Tradegate|